Adial Pharmaceuticals, Inc ADIL
$3.98
-9.34%
at last close
Analyst Consensus
- Consensus Rating
- Buy (3 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $6.17
- Implied Upside
- +54.9%
- Price Target Range
- $1.50 – $11.00
- Analysts (12 mo)
- 3
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-03 | Alliance Global PartnersJames Molloy |
Initiates coverage on | Buy | $11 |
| 2026-06-15 | LUCID CAPITAL MARKETSElemer Piros |
Initiates coverage on | Buy | $6 |
| 2025-09-30 | Maxim GroupJason McCarthy |
Upgrades | Hold → Buy | $2 |
| 2024-11-14 | Rodman & RenshawBrandon Folkes |
Initiates coverage on | Buy | $8 |
| 2023-07-11 | Brookline CapitalKumaraguru Raja |
Reiterates | Buy | $150 |
| 2022-08-17 | Maxim GroupJason McCarthy |
Downgrades | Buy → Hold | — |
| 2021-10-13 | Brookline CapitalKumaraguru Raja |
Initiates coverage on | Buy | $300 |
| 2021-06-29 | Litchfield HillsTheodore O'Neill |
Initiates coverage on | Buy | $125 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.98
- Market Cap
- $9.43 million
- 52-Week Range
- $1.31 – $18.90
- Average Volume
- 56K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.